Trial: 201608007

A Randomized Double-Blind Phase III Study Of Ibrutinib During And Following Autologous Stem Cell Transplantation Versus Placebo In Patients with Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Of The Activated B-Cell Subtype

Phase

III

Principal Investigator

Cashen, Amanda

Disease Site

Bone Marrow Transplant; Non-Hodgkin’s Lymphoma

Learn more about this study at: clinicaltrials.gov